- Insider Monkey via Yahoo FinanceMay 02 16:42 PM
We will study how this market volatility affected their sentiment towards Aerie Pharmaceuticals Inc (NASDAQ:AERI) during the quarter below.
- The Chattanoogan5 days ago
- Thomson Reuters StreetEvents via Yahoo Finance4 days ago
- Market Watch5 days ago
- Zacks via Yahoo FinanceMay 03 13:51 PM
This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below. Earnings ESP: Catalyst Pharma has an Earnings ESP of 0.00%.
- Zacks via Yahoo FinanceMay 02 14:11 PM
BioDelivery Sciences International, Inc. BDSI is scheduled to report first-quarter 2019 results on May 6 after market close. In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate.
- Zacks via Yahoo FinanceMay 10 18:41 PM
Branded - Sterile Injectables segment and the Specialty Products portfolio of Branded Pharmaceuticals segment. Quarterly Highlights Endo has four reportable business segments — ...
The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To DebutBenzinga via Yahoo FinanceMay 09 11:56 AM
The biotech company developing therapies and food to treat metabolic dysregulation in the liver is to list its shares on the Nasdaq under the ticker symbol AXLA. Cortexyme, which develops a ...
- Zacks via Yahoo FinanceMay 07 13:40 PM
BioDelivery Sciences International, Inc. BDSI incurred a loss of 5 cents per share for first-quarter 2019, narrower than the Zacks Consensus Estimate of a loss of 8 cents. The top line ...
- Thomson Reuters StreetEvents via Yahoo FinanceMay 15 6:33 AM
At the ENDO meeting in March, there was a well attended oral session dedicated to pheo and para, which highlighted AZEDRA...? --------------------------------------------------------- ...
- Bloomberg via Yahoo FinanceMay 02 21:30 PM
Federal jurors in Boston found that Kapoor conspired with four other executives to bribe doctors to pump up sales of Subsys and duped insurers into covering shady prescriptions. Former vice ...
- Thomson Reuters StreetEvents via Yahoo FinanceMay 15 4:55 AM
Moving to our CCH development program for assessing the treatment of cellulite...submission with a target market launch in the second half of 2020, subject to FDA approval. As part of our plan ...
- related to Endo Pharmaceuticals Inc